[Effect of concomitant use of immunomodulator (OK-432 and/or PSK) on advanced lung cancer (squamous cell carcinoma and adenocarcinoma) treated with radiation with combined chemotherapy].
D000230:Adenocarcinoma / Q000628:therapy*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D011509:Proteoglycans / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D000903:Antibiotics, Antineoplastic; D001688:Biological Products; D011509:Proteoglycans; D010844:Picibanil; C010770:polysaccharide-K